Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Seaman, Michael
Item TypeName
Academic Article Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Academic Article The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.
Academic Article Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Academic Article Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Academic Article Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
Academic Article Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.
Academic Article Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes.
Academic Article Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.
Concept Vaccinia virus
Academic Article HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
Academic Article First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Academic Article Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
Academic Article Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Search Criteria
  • Vaccinia virus
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.